Waters (WAT) Earnings Date & Reports

Key Takeaways

• Revenue beat: Waters reported total Q2 2026 revenue of $1.645 billion, exceeding the consensus estimate of approximately $1.62 billion.
• EPS at top of range: Adjusted earnings per share (EPS) came in at $3.05, narrowly ahead of the $3.01 consensus and at the high end of management's guidance.
• Organic momentum: Organic revenue grew 7% as reported and 9% in constant currency, driven by broad-based demand in pharmaceutical and industrial end markets.
• Acquired business outperformance: Biosciences and Diagnostic Solutions revenue of $817 million surpassed guidance by $15 million, reflecting early traction from integration initiatives.
• Full-year guidance raised: Management lifted its 2026 adjusted EPS outlook to $14.45–$14.65 and now expects organic constant currency revenue growth of 7% to 9%.

Earnings Context and Why It Matters

Waters Corporation's Q2 2026 results represent the second full quarter following its transformative acquisition of Becton Dickinson's biosciences and diagnostics businesses, which closed in February 2026. This report is pivotal for investors because it provides the clearest picture yet of how the legacy analytical instruments franchise and the newly acquired operations are performing under one roof. The combined entity now generates over $1.6 billion in quarterly revenue, substantially larger than Waters' pre-acquisition scale. With the integration still in its early stages, this quarter offered critical evidence on whether management's ambitious growth revitalization plan for the acquired assets is working — and the initial numbers suggest it is ahead of schedule.

Reported Results

Waters posted second-quarter total revenue of $1.645 billion, comfortably above the $1.62 billion consensus estimate. Organic revenue — excluding the acquired biosciences and diagnostics businesses — reached $828 million, representing 7% reported growth and 9% growth in constant currency. Adjusted EPS landed at $3.05, beating the consensus of $3.01 by approximately 1.3% and matching the top of the company's own guidance range.

On a GAAP (Generally Accepted Accounting Principles) basis, the company recorded a net loss of $1.39 per share, reflecting acquisition-related intangible amortization and integration charges. Adjusted gross margin was 54%, while adjusted operating margin stood at 25%. Free cash flow for the quarter totaled $202 million.

By division, the Analytical Sciences Division led with $669 million in revenue, up 9% in constant currency, fueled by 8% instrument growth and double-digit chemistry consumables expansion. The Advanced Diagnostics Division contributed $521 million (up 7%), the Biosciences Division generated $368 million (up 3%), and the Materials Science Division added $87 million (up 8% in constant currency).

AI Screener

For investors seeking to identify earnings-driven opportunities beyond Waters, Tickeron's AI Screener offers a powerful way to navigate the market. This AI-powered stock and ETF discovery tool enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, and performance metrics. By combining fundamental data with AI-driven signals, the screener can surface trending stocks, breakout candidates, and trade ideas more efficiently than manual screening. Whether you track the life sciences tools sector or broader industrial markets, the AI Screener provides a structured approach to finding actionable opportunities aligned with your strategy.

Market Reaction and Investor Sentiment

Initial market reaction to the Q2 report was mixed. Waters shares dipped roughly 1.26% in premarket trading to $370, as some investors appeared to have hoped for a larger earnings beat beyond the modest 1.3% upside. However, sentiment shifted during regular trading hours, and the stock ultimately closed at $389.32, up 3.89% from the prior close of $374.74. The recovery suggested that market participants ultimately gravitated toward the underlying strength of the results — particularly the organic growth acceleration, the faster-than-expected improvement in the acquired businesses, and the raised full-year outlook. The company's elevated valuation, with a forward P/E (price-to-earnings) ratio in the mid-20s, remains a point of debate among analysts, but the consensus view leans positive given the durable growth trajectory.

Forward Outlook and Key Factors to Monitor

Waters enters the second half of 2026 with notable momentum. Management raised full-year adjusted EPS guidance to $14.45–$14.65, implying 10% to 12% growth, and now projects organic constant currency revenue growth of 7% to 9%. For the third quarter specifically, the company guided for total revenue of $1.745 billion to $1.762 billion and adjusted EPS of $3.95 to $4.05.

Several catalysts merit attention in the months ahead. First, the upcoming launch of the FACSDiscover A7 Cell Analyzer in September targets a substantial instrument replacement opportunity — approximately 10,000 of the roughly 25,000 installed flow cytometry systems are considered aged and potentially due for refresh. Second, the BACTEC FXI Culture System, now cleared for U.S. commercialization, addresses more than 12,000 aged BACTEC systems that may enter a replacement cycle.

Investors should also monitor the trajectory of the acquired biosciences and diagnostics operations. Management's 180-day revitalization plan has already lifted growth to mid-single digits, and the company expects to exit 2026 at 6% or better. Pricing discipline in the acquired portfolio improved to 90 basis points in Q2, with a longer-term target of 150 basis points.

On the macro front, Waters identified pharmaceutical reshoring as a multi-year tailwind, tracking 76 individual U.S. manufacturing expansion sites — 37 of which are now under construction — representing an estimated $100 billion in total capital expenditure. With 71% of tracked sites linked to customer accounts where Waters holds medium or high market share, the company appears well-positioned to capture a meaningful portion of associated analytical instrumentation demand as these facilities come online between 2027 and 2030.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations